These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38697291)

  • 1. A long-acting LEAP2 analog reduces hepatic steatosis and inflammation and causes marked weight loss in mice.
    Shankar K; Metzger NP; Lawrence C; Gupta D; Osborne-Lawrence S; Varshney S; Singh O; Richard CP; Zaykov AN; Rolfts R; DuBois BN; Perez-Tilve D; Mani BK; Hammer STG; Zigman JM
    Mol Metab; 2024 Jun; 84():101950. PubMed ID: 38697291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LEAP2 deletion in mice enhances ghrelin's actions as an orexigen and growth hormone secretagogue.
    Shankar K; Metzger NP; Singh O; Mani BK; Osborne-Lawrence S; Varshney S; Gupta D; Ogden SB; Takemi S; Richard CP; Nandy K; Liu C; Zigman JM
    Mol Metab; 2021 Nov; 53():101327. PubMed ID: 34428557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
    Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D
    Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
    Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
    Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver-expressed antimicrobial peptide 2 functions independently of growth hormone secretagogue receptor in calorie-restricted mice.
    Islam MN; Zhang W; Sakai K; Nakazato Y; Tanida R; Sakoda H; Takei T; Takao T; Nakazato M
    Peptides; 2022 May; 151():170763. PubMed ID: 35151767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
    Nestor JJ; Parkes D; Feigh M; Suschak JJ; Harris MS
    Sci Rep; 2022 Apr; 12(1):6666. PubMed ID: 35461369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Grape pomace reduces the severity of non-alcoholic hepatic steatosis and the development of steatohepatitis by improving insulin sensitivity and reducing ectopic fat deposition in mice.
    Daniel T; Ben-Shachar M; Drori E; Hamad S; Permyakova A; Ben-Cnaan E; Tam J; Kerem Z; Rosenzweig T
    J Nutr Biochem; 2021 Dec; 98():108867. PubMed ID: 34571189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source.
    Boland ML; Oró D; Tølbøl KS; Thrane ST; Nielsen JC; Cohen TS; Tabor DE; Fernandes F; Tovchigrechko A; Veidal SS; Warrener P; Sellman BR; Jelsing J; Feigh M; Vrang N; Trevaskis JL; Hansen HH
    World J Gastroenterol; 2019 Sep; 25(33):4904-4920. PubMed ID: 31543682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dietary regulation of LEAP2 depends on meal composition in mice.
    Gradel AKJ; Holm SK; Byberg S; Merkestein M; Hogendorf WFJ; Lund ML; Buijink JA; Damgaard J; Lykkesfeldt J; Holst B
    FASEB J; 2023 Jun; 37(6):e22923. PubMed ID: 37104087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel fatty acid mimetic with pan-PPAR partial agonist activity inhibits diet-induced obesity and metabolic dysfunction-associated steatotic liver disease.
    Sahin C; Melanson JR; Le Billan F; Magomedova L; Ferreira TAM; Oliveira AS; Pollock-Tahari E; Saikali MF; Cash SB; Woo M; Romeiro LAS; Cummins CL
    Mol Metab; 2024 Jul; 85():101958. PubMed ID: 38763495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mismatched effects of receptor interacting protein kinase-3 on hepatic steatosis and inflammation in non-alcoholic fatty liver disease.
    Saeed WK; Jun DW; Jang K; Ahn SB; Oh JH; Chae YJ; Lee JS; Kang HT
    World J Gastroenterol; 2018 Dec; 24(48):5477-5490. PubMed ID: 30622377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ghrelin receptor inverse agonists as a novel therapeutic approach against obesity-related metabolic disease.
    Abegg K; Bernasconi L; Hutter M; Whiting L; Pietra C; Giuliano C; Lutz TA; Riediger T
    Diabetes Obes Metab; 2017 Dec; 19(12):1740-1750. PubMed ID: 28544245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone secretagogue receptor signalling affects high-fat intake independently of plasma levels of ghrelin and LEAP2, in a 4-day binge eating model.
    Cornejo MP; Castrogiovanni D; Schiöth HB; Reynaldo M; Marie J; Fehrentz JA; Perello M
    J Neuroendocrinol; 2019 Oct; 31(10):e12785. PubMed ID: 31469195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic Deficiency of Augmenter of Liver Regeneration Predisposes to Nonalcoholic Steatohepatitis and Fibrosis.
    Kumar S; Verma AK; Rani R; Sharma A; Wang J; Shah SA; Behari J; Salazar Gonzalez R; Kohli R; Gandhi CR
    Hepatology; 2020 Nov; 72(5):1586-1604. PubMed ID: 32031683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioactive dipeptides mitigate high-fat and high-fructose corn syrup diet-induced metabolic-associated fatty liver disease via upregulation of Nrf2/HO-1 expressions in C57BL/6J mice.
    Wayal V; Hsieh CC
    Biomed Pharmacother; 2023 Dec; 168():115724. PubMed ID: 37852102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice.
    Trevaskis JL; Griffin PS; Wittmer C; Neuschwander-Tetri BA; Brunt EM; Dolman CS; Erickson MR; Napora J; Parkes DG; Roth JD
    Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G762-72. PubMed ID: 22268099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The LEAP2 Response to Cancer-Related Anorexia-Cachexia Syndrome in Male Mice and Patients.
    Varshney S; Shankar K; Kerr HL; Anderson LJ; Gupta D; Metzger NP; Singh O; Ogden SB; Paul S; Piñon F; Osborne-Lawrence S; Richard CP; Lawrence C; Mani BK; Garcia JM; Zigman JM
    Endocrinology; 2024 Sep; 165(11):. PubMed ID: 39331742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
    Magee N; Zou A; Ghosh P; Ahamed F; Delker D; Zhang Y
    J Biol Chem; 2020 Jan; 295(4):994-1008. PubMed ID: 31831621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.